Monday, 2nd of May 2016 |
J R Soc Interface. 2010 Nov 6; 7(52): 1537–1544.
Published online 2010 Apr 14. doi: 10.1098/rsif.2010.0086
Michiel van Boven,1,* Mirjam Kretzschmar,1,2 Jacco Wallinga,1,2 Philip D O´Neill,3 Ole Wichmann,4 and Susan Hahné1
1Centre for Infectious Disease Control, National Institute for Public Health and the Environment, PO Box 1, 3720 Bilthoven, The Netherlands
2Julius Center for Health Research & Primary Care, University Medical Center Utrecht, PO Box 85500, 3508 Utrecht, The Netherlands
3School of Mathematical Sciences, University of Nottingham, Nottingham NG7 2RD, UK
4Department for Infectious Disease Epidemiology, Robert Koch-Institute, DGZ-Ring 1, 13086 Berlin, Germany
*Author for correspondence (Email: ln.mvir@nevob.nav.leihcim).
Author information ▼ Article notes ► Copyright and License information ►
Received 2010 Feb 16; Accepted 2010 Mar 22.
Copyright © 2010 The Royal Society
This article has been cited by other articles in PMC.
Excerpts below; full text is at http://rsif.royalsocietypublishing.org/content/7/52/1537
We have obtained estimates of the reproduction number and vaccine efficacy of measles in a highly vaccinated public school. Our results confirm that measles virus is among the most transmissible of infectious diseases (Anderson & May 1991, p. 70), and suggest that it may even be more transmissible than hitherto thought. This indicates that even though estimated vaccine efficacy is high (0.997), this may not be enough to prevent major outbreaks unless the vaccination coverage is nearly 100 per cent. In fact, our results indicate that the vaccination coverage should be at least 0.971 (95% credible interval: 0.961–0.978). This high value is consistent with the experience of elimination in the Americas, where a high vaccination coverage augmented by catch-up campaigns was required for elimination, and it may help explain that outbreaks continue to occur in highly vaccinated populations in other parts of the World (Sutcliffe & Rea 1996; Paunio et al. 1998; Lynn et al. 2004; Yeung et al. 2005; Ong et al. 2007).
In our Bayesian analyses the unknown vaccination statuses are included as latent variables in a consistent framework. These analyses indicate that the 32 infected persons with unknown vaccination status are almost always unvaccinated (range: 31–32; median: 32), while the 338 uninfected persons with unknown vaccination status are mostly vaccinated (range: 332–338; median 338; table 2). These findings may seem surprising but can be understood if one realizes that if vaccine efficacy for susceptibility is high, it is far more probable that infected persons are unvaccinated than vaccinated, while the reverse is true for uninfected persons. Nevertheless, to investigate how the results are affected if some of the uninfected persons with unknown vaccination status are unvaccinated we have carried out analyses assuming that vaccination coverage in the uninfected persons with missing vaccination status corresponds to the observed vaccination coverage (782/(782 + 36) ≈ 0.96; figure 5). The analyses indicate that the basic reproduction number, vaccine efficacy, and critical vaccination coverage all decrease with increasing number of uninfected unvaccinated persons. Still, the estimated critical vaccination coverage remains higher than the vaccination coverage typically achieved in developed countries (0.958; 95% CI: 0.943–0.969).
More generally, in our main analyses (figures 22–4) imputation of the missing information is based on the likelihood contributions of the infectious contacts. One could take an alternative approach, based on the assumption that the probability that a person with missing vaccination status is vaccinated is determined by the observed vaccination coverage. For the specific case of the measles outbreak in Germany, however, it is difficult to reconcile the number of infections in the group with unknown vaccination status with the observed number of infections in the vaccinated and unvaccinated groups. To be specific, arguing along these lines one would expect out of 370 persons with unknown vaccination status to be unvaccinated. It is difficult to see how this figure can be matched with the observed number of infections in this group (32) and the infection attack rates in the unvaccinated and vaccinated groups (19/36 and 4/782).
Our definition of vaccine efficacy is based on an explicit epidemiological model, and has a clear-cut biological interpretation (reduction of the probability of infection per contact), making it possible to meaningfully average over populations and to extrapolate beyond the study population. This contrasts with traditional estimates of vaccine efficacy that are based on a comparison of attack rates in vaccinated and unvaccinated individuals, or by simply using the vaccination status of the infected individuals together with the population vaccination coverage (the screening method) (Orenstein et al. 1985). Vaccine efficacies estimated by these methods are lacking a clear biological interpretation, making it difficult to interpret the results and to extrapolate to different situations (Becker et al. 2003; Becker & Britton 2004; Halloran et al. 2010).
We have based our analyses on a single outbreak of measles in a single school, and one could argue that this limits the scope of our results. However, in recent years numerous measles outbreaks have been described in highly vaccinated populations (table 1), and we therefore believe that the critical vaccination coverage for measles virus may have been systematically underestimated. This could be due to the fact that estimates of measles reproduction numbers are often still based on serological studies from the pre-vaccination era. More recent analyses of outbreaks and long-term time series in the highly vaccinated populations of the Netherlands and the UK suggest that the fraction of the population that should be immune to prevent major outbreaks is approximately 96 per cent (Wallinga et al. 2003, 2005), and that the basic reproduction number is in the range 21–57 (Finkenstadt & Grenfell 2000; He et al. 2010; table 2).
Of course, we do not claim that measles basic reproduction numbers and vaccine efficacies are invariant, and do not differ between populations with differing contact intensities (e.g. households versus schools versus public space), vaccination composition and coverage, vital statistics (birth rates, life expectancy) and other demographic characteristics (e.g. age distribution, gender, socioeconomics). Still, we believe that it is of importance to analyse measles outbreaks of measles in high-contact settings such as households and schools because these may act as a multiplier of infection and driver of epidemics in heterogeneously vaccinated populations.
While we were able to obtain estimates of the efficacy of the vaccine in preventing infection in vaccinated persons, the design of the study makes it difficult to obtain estimates of the efficacy of the vaccine reducing the infectiousness of infected vaccinated persons (Basta et al. 2008). The reason is that with final size information from a single population it is difficult to disentangle the effect of the vaccine in reducing the probability of infection from the effect it may have in reducing infectiousness of infected vaccinated persons. To this end, other schools with different vaccination coverages and different attack rates in the vaccinated and unvaccinated subgroups should have been included. However, since the infection attack rates in vaccinated persons are very low in the German outbreak (Wichmann et al. 2009) the precision with which one can estimate the efficacy of the vaccine in reducing the infectiousness of infected vaccinated persons is likely to be poor.
Our finding that infected vaccinated individuals are to be expected despite the fact that vaccine efficacy is very high shows that the effectiveness of a vaccine in a population cannot be judged solely by its (estimated) efficacy, but also depends on the pathogen´s transmissibility. If vaccines are judged by their ability to induce herd immunity, then the requirements for what constitutes an adequate vaccine are much more stringent for a highly transmissible infectious disease such as measles than for other, less transmissible, infectious diseases. For instance, while for most infectious diseases a vaccine that is able to prevent transmission in more than 99.5 per cent of infectious contacts will certainly be able to prevent major outbreaks with current vaccination coverages, this is arguably not always the case for measles.
We would like to acknowledge the constructive comments of three anonymous reviewers which helped improve the manuscript.
Mossong J, Muller CP. Epidemiol Infect. 2000 Apr; 124(2):273-8.
Wichmann O, Hellenbrand W, Sagebiel D, Santibanez S, Ahlemeyer G, Vogt G, Siedler A, van Treeck U. Pediatr Infect Dis J. 2007 Sep; 26(9):782-6.
Mori N, Ohkusa Y, Ohyama T, Tanaka-Taya K, Taniguchi K, Kobayashi JM, Doy M, Okabe N. Pediatr Int. 2008 Aug; 50(4):464-8.
Cutts FT, Dabis F. Sante. 1994 May-Jun; 4(3):163-71.
Hellenbrand W, Siedler A, Tischer A, Meyer C, Reiter S, Rasch G, Teichmann D, Santibanez S, Altmann D, Claus H, et al. J Infect Dis. 2003 May 15; 187 Suppl 1:S208-16.
Sequera VG, Valencia S, García-Basteiro AL, Marco A, Bayas JM. Human Vaccines & Immunotherapeutics. 1/01/01 00:00; 11(11)2615-2626
Choe YJ, Jee Y, Oh MD, Lee JK. Journal of Korean Medical Science. 2015/11/01 00:00; 30(Suppl 2)S115-S121
Edens C, Collins ML, Goodson JL, Rota PA, Prausnitz MR. Vaccine. 2015/09/08 00:00; 33(37)4712-4718
Schweitzer A, Krause G, Pessler F, Akmatov MK. BMC Public Health. 1/01/01 00:00; 15798
Althaus CL, Salathé M. Emerging Infectious Diseases. 2015/08/01 00:00; 21(8)1480-1481
Yeung LF, Lurie P, Dayan G, Eduardo E, Britz PH, Redd SB, Papania MJ, Seward JF
Pediatrics. 2005 Dec; 116(6):1287-91.
Muscat M, Bang H, Wohlfahrt J, Glismann S, Mølbak K, EUVAC.NET Group
Lancet. 2009 Jan 31; 373(9661):383-9.
Wallinga J, Teunis P, Kretzschmar M
Vaccine. 2003 Jun 2; 21(19-20):2643-50.
Wallinga J, Heijne JC, Kretzschmar M
PLoS Med. 2005 Nov; 2(11):e316.
Sutcliffe PA, Rea E
CMAJ. 1996 Nov 15; 155(10):1407-13.
Paunio M, Peltola H, Valle M, Davidkin I, Virtanen M, Heinonen OP
Am J Epidemiol. 1998 Dec 1; 148(11):1103-10.
Lynn TV, Beller M, Funk EA, Middaugh JP, Ritter D, Rota PA, Bellini WJ, Torok TJ
J Infect Dis. 2004 May 1; 189 Suppl 1():S86-90.
Ong G, Rasidah N, Wan S, Cutter J
Singapore Med J. 2007 Jul; 48(7):656-61.
See more ...
Wichmann O, Hellenbrand W, Sagebiel D, Santibanez S, Ahlemeyer G, Vogt G, Siedler A, van Treeck U
Pediatr Infect Dis J. 2007 Sep; 26(9):782-6.
Wichmann O, Siedler A, Sagebiel D, Hellenbrand W, Santibanez S, Mankertz A, Vogt G, Treeck Uv, Krause G
Bull World Health Organ. 2009 Feb; 87(2):108-15.
Becker NG, Britton T, O´Neill PD
Biometrics. 2003 Sep; 59(3):467-75.
Wichmann O, Siedler A, Sagebiel D, Hellenbrand W, Santibanez S, Mankertz A, Vogt G, Treeck Uv, Krause G
Bull World Health Organ. 2009 Feb; 87(2):108-15.
Wichmann O, Hellenbrand W, Sagebiel D, Santibanez S, Ahlemeyer G, Vogt G, Siedler A, van Treeck U
Pediatr Infect Dis J. 2007 Sep; 26(9):782-6.
Orenstein WA, Bernier RH, Dondero TJ, Hinman AR, Marks JS, Bart KJ, Sirotkin B
Bull World Health Organ. 1985; 63(6):1055-68.
Wichmann O, Siedler A, Sagebiel D, Hellenbrand W, Santibanez S, Mankertz A, Vogt G, Treeck Uv, Krause G
Bull World Health Organ. 2009 Feb; 87(2):108-15.
Wichmann O, Hellenbrand W, Sagebiel D, Santibanez S, Ahlemeyer G, Vogt G, Siedler A, van Treeck U
Pediatr Infect Dis J. 2007 Sep; 26(9):782-6.
Wichmann O, Hellenbrand W, Sagebiel D, Santibanez S, Ahlemeyer G, Vogt G, Siedler A, van Treeck U
Pediatr Infect Dis J. 2007 Sep; 26(9):782-6.
Basta NE, Halloran ME, Matrajt L, Longini IM Jr
Am J Epidemiol. 2008 Dec 15; 168(12):1343-52.
van Boven M, Koopmans M, Du Ry van Beest Holle M, Meijer A, Klinkenberg D, Donnelly CA, Heesterbeek HJ
PLoS Comput Biol. 2007 Jul; 3(7):e145.
Sutcliffe PA, Rea E
CMAJ. 1996 Nov 15; 155(10):1407-13.
Paunio M, Peltola H, Valle M, Davidkin I, Virtanen M, Heinonen OP
Am J Epidemiol. 1998 Dec 1; 148(11):1103-10.
Lynn TV, Beller M, Funk EA, Middaugh JP, Ritter D, Rota PA, Bellini WJ, Torok TJ
J Infect Dis. 2004 May 1; 189 Suppl 1():S86-90.
Yeung LF, Lurie P, Dayan G, Eduardo E, Britz PH, Redd SB, Papania MJ, Seward JF
Pediatrics. 2005 Dec; 116(6):1287-91.
Ong G, Rasidah N, Wan S, Cutter J
Singapore Med J. 2007 Jul; 48(7):656-61.
Orenstein WA, Bernier RH, Dondero TJ, Hinman AR, Marks JS, Bart KJ, Sirotkin B
Bull World Health Organ. 1985; 63(6):1055-68.
Becker NG, Britton T, O´Neill PD
Biometrics. 2003 Sep; 59(3):467-75.
Wallinga J, Teunis P, Kretzschmar M
Vaccine. 2003 Jun 2; 21(19-20):2643-50.
Wallinga J, Heijne JC, Kretzschmar M
PLoS Med. 2005 Nov; 2(11):e316.
He D, Ionides EL, King AA
J R Soc Interface. 2010 Feb 6; 7(43):271-83.
Basta NE, Halloran ME, Matrajt L, Longini IM Jr
Am J Epidemiol. 2008 Dec 15; 168(12):1343-52.
Wichmann O, Siedler A, Sagebiel D, Hellenbrand W, Santibanez S, Mankertz A, Vogt G, Treeck Uv, Krause G
Bull World Health Organ. 2009 Feb; 87(2):108-15.
Assessment of Immune Status Against Measles, Mum ...
Assessment of Immune Status Against Measles, Mumps, and Rubella in Young Kuwaitis: MMR Vaccine Efficacy. Madi N, Altawalah H, Alfouzan W ...2017 M&RI Partners Meeting Presentations
The global Measles and Rubella Initiative meeting was held in Washington DC on 7th and 8th Sept. 2017. The meeting which was hosted by American Red Cr ...STORIES OF LIFE IN A CHANGING WORLD Scientists Cr ...
STORIES OF LIFE IN A CHANGING WORLD Scientists Crack a 50-Year-Old Mystery about the Measles Vaccine Worth a little pain? Back in 1990 a school bo ...20 most consulted measles and rubella articles in ...
Dear AllToday we share a review of the year 2016 regarding measles and rubella items posted on our web page. We shared articles on topics ranging from ...Region of the Americas is declared free of measles ...
More information on this great milestone can be found on url link belowhttp://www.paho.org/hq/index.php?option=com_content&view=article&id=125 ...Progress Toward Regional Measles Elimination — W ...
Progress Toward Regional Measles Elimination — Worldwide, 2000–2014 Morbidity and Mortality Weekly Report Best read, with ta ...Health Equity Initiative, New York, NY, 25-26 Febr ...
Health Equity Initiative, Summit, NYC, 25-26 February 2016 For details, consult http://www.healthequityinitiative.org/hei/programs/summit/REQUEST FOR PROPOSAL: MEASLES VACCINATION UNDER 9 ...
1 REQUEST FOR PROPOSAL: Measles Vaccination Under 9 Months of Age APPLICATION SUBMISSION DATE: January 26, 2015 1. In ...CARTOON CHARACTERS JOIN THE FIGHT AGAINST MEASLES
[source] Measles and Rubella Initiative[|source]Thanks to reader Jane Wachira for pointing out the following weblink. Measles eradication consists not ...I LOVE/HATE THIS GLOBAL VACCINATION COVERAGE GRAPH ...
[source]Rosling s FactPod[|source]This video from Hans Rosling explaining what he loves with global measles vaccination coverage trends namely rapid i ...POWER POINT PRESENTATIONS FROM THE 13TH ANNUAL ADV ...
[source]Measles and Rubella Initiative[|source]The Measles and Rubella Initiative has spent much effort fighting for its cause by means of widespread ...CALLING THE SHOTS
[source]PBS Network[|source]"VACCINES -- CALLING THE SHOTS" This TV program, broadcast on the PBS network, looks at the commonest arguments by anti-v ...COMBATING HEALTHCARE CORRUPTION AND FRAUD WITH IMP ...
[source]BMC International Health and Human Rights[|source]Corruption is a serious threat to global health outcomes, leading to financial waste and adv ...CORRUPTION KILLS: ESTIMATING THE GLOBAL IMPACT OF ...
[source]PLoS One[|source]Many countries still have high levels of child mortality, particularly in sub-Saharan Africa and South Asia, and in recent ye ...READY OR NOT: RESPONDING TO MEASLES IN THE POSTELI ...
[source]Annals of Internal Medicine[|source]Opnion Paper Although endemic measles was eliminated in the United States in 2000, two concurrent measle ...RUBELLA AND CONGENITAL RUBELLA SYNDROME CONTROL AN ...
[source]Morbidity and Mortality Weekly Report (MMWR)[|source]In 2011, the World Health Organization (WHO) updated guidance on the preferred strategy f ...PROGRESS TOWARDS MEASLES ELIMINATION – EASTERN M ...
[source]Weekly Epidemiological Record (WER)[|source]During the period 2008–2012, regional progress towards measles elimination stagnated, and th ...THE IMMUNIZATION PROGRAMME THAT SAVED MILLIONS OF ...
[source]Bulletin of the WHO[|source]In the world vaccination week, the Bulletin of the World Health Organization outlines the history, status and impa ...HEALTH SYSTEM COST OF DELIVERING ROUTINE VACCINATI ...
[source]Bulletin of the WHO[|source]On the eve of the 40th anniversary of launching of the Expanded Programme on Immunization (EPI) in 1974, during th ...World Immunization Week
[source]WHO/IVB Publication[|source]Never miss another jab, The slogan for World Immunization Week 2014 is “Immunize for a healthy future: Know ...Measles: know the risks, check your status, protec ...
[source]WHO/IVB Publication[|source]Measles is a highly contagious, serious disease caused by a virus. In 1980, before widespread vaccination, measles ...THE RIGHTS OF THE UNVACCINATED CHILD: THE LEGAL FR ...
[source]Los Angeles Times[|source]In light of what s starting to look like a surge of measles cases spread by unvaccinated carriers, Hasting ...Consultants: Measles and rubella control/eliminati ...
[source]Technical Network for Strengthening EPI[|source]Announcement solicits interest from potential candidates to act as consultants for WHO through ...PUBLIC HEALTH OFFICIALS MARK 50TH YEAR OF MEASLES ...
[source]Journal of American Medical Association[|source]Until the 1960s, measles was a rite of passage for US children; nearly all had the disease bef ...THE TOLL OF THE ANTI-VACCINATION MOVEMENT, IN ONE ...
[source]Los Angelos Times[|source]Aaron Carroll today offers a graphic depiction of the toll of the anti-vaccination movement. It comes from a Council ...“Can we use $30 of the taxes you’re already pa ...
[source]Annual Letter of BMGF[|source]If you were asked this question today, what answer would you give? Bill and Melinda Gates ask, "Would you check ...REACHING HARD-TO-REACH INDIVIDUALS: NONSELECTIVE V ...
[source]American Journal of Epidemiology[|source]Source: American Journal of Epidemiology The World Health Organization guidelines for response to me ...Rubella and Congenital rubella syndrome control an ...
[source]Weekly Epidemiological Record (WER)[|source]Full text record of Rubella and CRS control/elimination are available at http://www.who.int/wer/20 ...Measles Press Conference at CDC: 50th Anniversary ...
[source]CDC Media Release, 5th Dec[|source]Full text, video and question and answer session for journalists all avalable at http://www.cdc.gov/media/r ...A bibliometric analysis of childhood immunization ...
[source]BMC Medicine[|source]During the past four decades national EPI programs have developed or adapted and implemented a broad range of strategies ...Lessons from the tragic measles outbreak in Samoa
Monday, 9th of March 2020 |
Characterisation of diversity of measles viruses in India: genomic sequencing and comparative genomics studies.
Monday, 9th of March 2020 |
The elimination of measles in Iran
Monday, 9th of March 2020 |
Measles-containing vaccines in Brazil: Coverage,
Monday, 9th of March 2020 |
Measles-containing vaccines in Brazil: Coverage, homogeneity of coverage and associations with contextual factors at municipal level.
Monday, 9th of March 2020 |
Website Views |
47358325 |